Trametinib 2 mg
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Metastatic Castrate Resistant Prostate Cancer
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Trial Timeline
โ โ โ
NCT ID
NCT03386071About Trametinib 2 mg
Trametinib 2 mg is a pre-clinical stage product being developed by Novartis for Progressive Metastatic Castrate Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03386071. Target conditions include Progressive Metastatic Castrate Resistant Prostate Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03386071 | Pre-clinical | Completed |
Competing Products
20 competing products in Progressive Metastatic Castrate Resistant Prostate Cancer